Shares of Iovance Biotherapeutics Inc. (IOVA) have lost a whopping 58% from their 52-week high of $18.33, recorded in February of this year, and trade around $7.
The company is focused on innovating, developing and delivering tumor infiltrating lymphocyte therapy for people with cancer.
Tumor infiltrating lymphocytes (TIL) are naturally occurring immune cells that vigilantly patrol and eliminate cancer cells. TIL recognize cancer through tumor markers on the surface of cancer cells that are unique to each person. However, when cancer grows and becomes widespread, the TIL are unable to perform their intended function. As a result, cancer cells can evade the immune system, exhausting the TIL and rendering them ineffective.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.